NCT01967043 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

September 30, 2016

Conditions

Solid Tumor

Interventions

DRUG

Oraxol

Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.

Trial Locations (3)

Roswell Park Cancer Institute, Buffalo

Johns Hopkins University, Baltimore

University of Colorado Cancer Center, Aurora